Director Joel Ackerman of Champions Oncology, Inc. filed a statement of changes in beneficial ownership on November 9, 2026, reporting the acquisition of options to purchase 31,216 shares of common stock on November 5, 2026.

Key Highlights

  • Reporting person: Joel Ackerman, identified as a Director of Champions Oncology, Inc. (NASDAQ:CSBR).
  • Security acquired: Options to purchase 31,216 shares of Common Stock, acquired on November 5, 2026, with transaction code "A" (acquired).
  • Exercise price: $4.76 per share, with an expiration date of November 5, 2036.
  • Vesting schedule: According to the filing, options vest and become exercisable over a twelve-month period, with vesting dates on November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027.
  • Resulting ownership: Following the reported transaction, Ackerman beneficially owns 31,216 derivative securities, held directly.

Director Option Grant Details at Champions Oncology

Champions Oncology, Inc., listed on NASDAQ under the symbol CSBR, is an oncology-focused company headquartered at One University Place, Suite 307, Hackensack, New Jersey 07601. The company operates in the oncology sector, and its directors file ownership reports with the SEC pursuant to Section 16(a) of the Securities Exchange Act of 1934.

According to the filing, the transaction recorded in Table II (Derivative Securities) reflects the acquisition of an option to purchase Common Stock. The option covers 31,216 shares, carries an exercise price of $4.76, and has a ten-year term running from November 5, 2026, through November 5, 2036. The filing notes that "the options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively." The filing was signed by Joel Ackerman on November 9, 2026.

No non-derivative securities transactions were reported in Table I of the filing. The filing was submitted by one reporting person and was not marked as an amendment to a prior filing. The ownership form for the derivative security is listed as direct.

What Was Disclosed

The filing discloses that director Joel Ackerman acquired options to purchase 31,216 shares of Champions Oncology common stock at $4.76 per share on November 5, 2026, with vesting spread across four quarterly dates over twelve months and an expiration in 2036.